Cytochrome P450: 2. Pharmacogenetics

Australian Journal of Hospital Pharmacy

Volumn 30, Issue 3, 2000, Pages 102-105

  McKinnon, Ross A ^a   Evans, Allan M ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DIMETHYLNITROSAMINE DEMETHYLASE; PHENACETIN O DEETHYLASE; UNCLASSIFIED DRUG;

ALLELE; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PHENOTYPE; RECOMBINANT DNA TECHNOLOGY; REGULATOR GENE; SHORT SURVEY; STRUCTURAL GENE;

EID: 0033937464     PISSN: 03106810     EISSN: None     Source Type: Journal    
DOI: 10.1002/jppr2000303102     Document Type: Article

References (29)

1. Motulsky A. Drug reactions, enzymes and biochemical genetics. JAMA 1957; 165: 835-7.
2. Kalow W. Pharmacogenetics - heredity and the response to drugs. Philadelphia: WB Saunders Company; 1962.
3. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996; 15: 273-80.
4. Homepage of the human cytochrome P450 (CYP) allele nomenclature committee. http://www.imm.ki.se/CYPalleles/ updated 20 November 1999.
5. Watanabe W. Polymorphic CYP genes and disease predisposition - what have the studies shown so far? Tox Lett 1998; 102-3: 167-71.
6. McKinnon RA, Hall P de la M, Quattrochi LC, Tukey RH, McManus ME. Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology 1991; 14: 848-56.
7. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 1993; 3: 239-49.
8. Tang BK, Zhou Y, Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994; 4: 117-24.
9. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-27.
10. Welfare MR, Aitkin M, Bassendine MF, Daly AK. Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics 1999; 9: 367-75.
11. Huang JD, Quo WC, Lai MD, Guo YL, Lambert GH. Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos 1999; 27: 98-101.
12. Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther 1993; 57: 129-60.
13. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature 1998; 393: 750.
14. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-19.
15. Rettie AE, Haining RL, Bajpai M, Levy RH. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Research 1999; 35: 253-5.
16. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-22.
17. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285-99.
18. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmac Ther 1989; 43: 53-76.
19. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16: 183-7.
20. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.
21. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-9.
22. McLellan RA, Oscarson M, Seidegard J, Evans DAP, Ingelman-Sudberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7: 181-91.
23. Caraco Y, Sheller J, Wood AJ. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther 1999; 290: 413-22.
24. Sallustio BC, Morris RG. Assessment of interlaboratory performance in the provision of perhexiline therapeutic drug monitoring services in Australia. Ther Drug Monit 1999; 21: 389-94.
25. Larrey D, Pageaux GP Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26: 12-21.
26. Hu Y, Oscarson M, Johansson I, Yue QY, Dahl ML, Tabone M. Genetic polymorphism of human CYP2E1 : characterization of two variant alleles. Mol Pharmacol 1997; 51: 370-6.
27. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. J Pharmacol Exp Ther 1994; 270: 414-23.
28. McKinnon RA, Burgess WM, Hall P de la M, Gonzalez FJ, Roberts-Thomson SJ, McManus ME. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 1995; 36: 259-67.
29. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225-9.